Global Transfusion Diagnosis for Donor Market Growth (Status and Outlook) 2026-2032
Description
The global Transfusion Diagnosis for Donor market size is predicted to grow from US$ 4402 million in 2025 to US$ 6479 million in 2032; it is expected to grow at a CAGR of 5.7% from 2026 to 2032.
The gross profit margin of major companies in the industry is between 50% – 70%.
Transfusion Diagnosis for Donors refers to the critical medical screening and testing process performed on blood donors to ensure the safety and compatibility of blood products. This includes mandatory screening for transfusion-transmitted infections (TTIs) such as HIV, Hepatitis B and C, and Syphilis using Nucleic Acid Testing (NAT) and ELISA. It also encompasses blood group serology (ABO/Rh typing) and cross-matching. These procedures are fundamental to modern hemovigilance, ensuring every blood unit meets stringent clinical safety standards to prevent adverse reactions in recipients.
The industrial chain begins upstream with providers of biological raw materials (antigens, antibodies, enzymes), precision optical sensors, microfluidic chips, and high-purity reagents. The midstream consists of manufacturers of automated blood screening platforms, molecular diagnostic systems, and immunoassays. Downstream applications include national and regional blood centers, hospital blood banks, and plasma collection stations. The chain is supported by cold-chain logistics providers and regulatory bodies. Service providers offer calibration, system maintenance, and integrated blood management software to track blood units from collection to clinical transfusion, ensuring full traceability and safety.
The market for transfusion diagnosis is witnessing a significant shift toward automated and molecular-based testing to minimize the "window period" of infection detection. Increasing global healthcare expenditures and aging populations are driving the demand for safe blood supplies. A key trend is the integration of Nucleic Acid Testing (NAT) with traditional serology to enhance sensitivity. Furthermore, the adoption of Big Data and AI in blood management systems is optimizing inventory and reducing wastage. While stringent regulatory requirements pose a high entry barrier, the expansion of blood banking infrastructure in emerging economies provides substantial growth opportunities. Manufacturers are focusing on high-throughput systems that reduce manual errors while maintaining the highest levels of diagnostic accuracy and safety.
LPI (LP Information)' newest research report, the “Transfusion Diagnosis for Donor Industry Forecast” looks at past sales and reviews total world Transfusion Diagnosis for Donor sales in 2025, providing a comprehensive analysis by region and market sector of projected Transfusion Diagnosis for Donor sales for 2026 through 2032. With Transfusion Diagnosis for Donor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transfusion Diagnosis for Donor industry.
This Insight Report provides a comprehensive analysis of the global Transfusion Diagnosis for Donor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Transfusion Diagnosis for Donor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transfusion Diagnosis for Donor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transfusion Diagnosis for Donor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transfusion Diagnosis for Donor.
This report presents a comprehensive overview, market shares, and growth opportunities of Transfusion Diagnosis for Donor market by product type, application, key players and key regions and countries.
Segmentation by Type:
Instruments
Kits and Reagents
Segmentation by Diagnostic Purpose:
Blood Grouping & Typing Diagnostics
Infectious Disease Screening Diagnostics
Segmentation by Testing Method:
Immunoassay-Based Diagnostics
Molecular Diagnostics
Segmentation by Application:
Blood Banks
Blood Donation/Transfusion Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Grifols
F. Hoffmann-La Roche
Abbott
Bio-Rad Laboratories
Werfen
QuidelOrtho Corporation
AliveDx Holdings Finance
BAG Diagnostics GmbH
Diasorin
Prestige Diagnostics
Atlas Medical GmbH
Lorne Laboratories
Please note: The report will take approximately 2 business days to prepare and deliver.
The gross profit margin of major companies in the industry is between 50% – 70%.
Transfusion Diagnosis for Donors refers to the critical medical screening and testing process performed on blood donors to ensure the safety and compatibility of blood products. This includes mandatory screening for transfusion-transmitted infections (TTIs) such as HIV, Hepatitis B and C, and Syphilis using Nucleic Acid Testing (NAT) and ELISA. It also encompasses blood group serology (ABO/Rh typing) and cross-matching. These procedures are fundamental to modern hemovigilance, ensuring every blood unit meets stringent clinical safety standards to prevent adverse reactions in recipients.
The industrial chain begins upstream with providers of biological raw materials (antigens, antibodies, enzymes), precision optical sensors, microfluidic chips, and high-purity reagents. The midstream consists of manufacturers of automated blood screening platforms, molecular diagnostic systems, and immunoassays. Downstream applications include national and regional blood centers, hospital blood banks, and plasma collection stations. The chain is supported by cold-chain logistics providers and regulatory bodies. Service providers offer calibration, system maintenance, and integrated blood management software to track blood units from collection to clinical transfusion, ensuring full traceability and safety.
The market for transfusion diagnosis is witnessing a significant shift toward automated and molecular-based testing to minimize the "window period" of infection detection. Increasing global healthcare expenditures and aging populations are driving the demand for safe blood supplies. A key trend is the integration of Nucleic Acid Testing (NAT) with traditional serology to enhance sensitivity. Furthermore, the adoption of Big Data and AI in blood management systems is optimizing inventory and reducing wastage. While stringent regulatory requirements pose a high entry barrier, the expansion of blood banking infrastructure in emerging economies provides substantial growth opportunities. Manufacturers are focusing on high-throughput systems that reduce manual errors while maintaining the highest levels of diagnostic accuracy and safety.
LPI (LP Information)' newest research report, the “Transfusion Diagnosis for Donor Industry Forecast” looks at past sales and reviews total world Transfusion Diagnosis for Donor sales in 2025, providing a comprehensive analysis by region and market sector of projected Transfusion Diagnosis for Donor sales for 2026 through 2032. With Transfusion Diagnosis for Donor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transfusion Diagnosis for Donor industry.
This Insight Report provides a comprehensive analysis of the global Transfusion Diagnosis for Donor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Transfusion Diagnosis for Donor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transfusion Diagnosis for Donor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transfusion Diagnosis for Donor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transfusion Diagnosis for Donor.
This report presents a comprehensive overview, market shares, and growth opportunities of Transfusion Diagnosis for Donor market by product type, application, key players and key regions and countries.
Segmentation by Type:
Instruments
Kits and Reagents
Segmentation by Diagnostic Purpose:
Blood Grouping & Typing Diagnostics
Infectious Disease Screening Diagnostics
Segmentation by Testing Method:
Immunoassay-Based Diagnostics
Molecular Diagnostics
Segmentation by Application:
Blood Banks
Blood Donation/Transfusion Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Grifols
F. Hoffmann-La Roche
Abbott
Bio-Rad Laboratories
Werfen
QuidelOrtho Corporation
AliveDx Holdings Finance
BAG Diagnostics GmbH
Diasorin
Prestige Diagnostics
Atlas Medical GmbH
Lorne Laboratories
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
118 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Transfusion Diagnosis for Donor Market Size by Player
- 4 Transfusion Diagnosis for Donor by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Transfusion Diagnosis for Donor Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
